nuchal translucency


Also found in: Acronyms.

nuchal translucency

(nū'kăl trans-lū'sen-sē),
ultrasonographic finding of a single nonseptated lucenty (anechoic area) projecting from the posterior aspect of the fetal neck; measured at menstrual age 11-14 weeks. Increased thickness of this area indicates increased fetal risk for aneuploidy and some nonchromosomal disorders.
References in periodicals archive ?
8220;Whilst I was the Director of Foetal Medicine at Corniche Hospital in Abu Dhabi, a review of foetal medicine statistics showed that the number of women who had risk assessment using nuchal translucency was only 6%,” says Dr Ramanathan.
The nuchal translucency (NT), which is the fluid behind the foetal neck, is measured between 11-14 weeks to determine the risk of the foetus having not only a chromosomal abnormality, but also cardiac, other structural abnormality in the foetus, or a genetic disorder.
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Nuchal translucency measurements may not be obtainable in 10% to 15% of patients.
For example, the Fetal Medicine Foundation (Studio City, California) recommends a range of 45 to 84 mm and 11 weeks, 0 days, to 13 weeks, 6 days, (11) whereas the Nuchal Translucency Quality Review program recommends a range of 38 to 84 mm and 10 weeks, 3 days, to 13 weeks, 6 days.
The combination of nuchal translucency and assay of maternal serum free hCGB and PAPP-A improves the detection of affected fetuses.
NEW ORLEANS -- First-trimester aneuploid screening using maternal age, biochemistry, and nuchal translucency measurement is "possible, accurate, and reliable," and should be more widely adopted, Dr.
Thirteen medical centers in the United States are conducting a federally funded clinical trial on a similar test, called the First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening, WebMD Medical News reported.
Although she decided against amniocentesis, she has undergone a special ultrasound scan called a nuchal translucency.
Over the past two years, the global prenatal testing market has witnessed a paradigm shift from conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS) to non-invasive prenatal testing.
The market for non-invasive prenatal testing is evolving rapidly due the advantages it offers over the conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis and chorionic villus sampling (CVS).
With the first-trimester screening approach that combines maternal serum free beta-human chorionic gonadotropin (free beta-HCG) and pregnancy-associated plasma protein A (PAPP-A) with fetal nuchal translucency measurement, we are able to detect upward of 85% of fetuses with Down syndrome, or trisomy 21.